<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04666714</url>
  </required_header>
  <id_info>
    <org_study_id>EMS1719 - PRAGA</org_study_id>
    <nct_id>NCT04666714</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain</brief_title>
  <official_title>National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Praga formulation in the&#xD;
      treatment of neuropathic pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in pain intensity.</measure>
    <time_frame>3 months</time_frame>
    <description>The change in pain intensity from baseline after 3 months of treatment will be scored by Numerical Rating Scale from 0 to 10 points, with 0 = no pain and 10 = worst possible pain, recorded in a participant diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study.</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence and severity of adverse events recorded during the study will be determined over 6 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Praga formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study is double-dummy. The participant must take pills twice a day, as follows:&#xD;
Morning:Placebo pregabalin tablet, oral Night: Placebo pregabalin tablet, oral plus Praga formulation,oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study is double-dummy. The participant must take pills twice a day, as follows:&#xD;
Morning:Pregabalin tablet, oral Night: Pregabalin tablet plus, oral placebo Praga formulation, oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Praga formulation</intervention_name>
    <description>Praga formulation tablet</description>
    <arm_group_label>Praga formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo pregabalin 75mg</intervention_name>
    <description>Placebo pregabalin 75mg tablet</description>
    <arm_group_label>Praga formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Pregabalin 150mg</intervention_name>
    <description>Placebo Pregabalin 150mg tablet</description>
    <arm_group_label>Praga formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 75mg</intervention_name>
    <description>Pregabalin 75mg tablet</description>
    <arm_group_label>Pregabalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 150mg</intervention_name>
    <description>Pregabalin 150mg tablet</description>
    <arm_group_label>Pregabalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Praga formulation</intervention_name>
    <description>Placebo Praga formulation tablet</description>
    <arm_group_label>Pregabalin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to confirm voluntary participation and agree to all trial purposes by signing&#xD;
             and dating the informed consent forms;&#xD;
&#xD;
          -  Participants of 18 years and older;&#xD;
&#xD;
          -  Diagnosis of type 2 or type 1 diabetes for at least 1 year;&#xD;
&#xD;
          -  No change in antidiabetic medication winthin 3 months;&#xD;
&#xD;
          -  Diagnosis of painful sensorimotor diabetic polyneuropathy;&#xD;
&#xD;
          -  Presence of at least one of the following symptoms: i. numbness in the toes, feet and&#xD;
             / or legs; ii. paresthesias (tingling and / or neuropathic pain) in the toes, feet and&#xD;
             / or legs.&#xD;
&#xD;
          -  Presence of at least one of the following signs: i. symmetrical hypoesthesia of&#xD;
             tactile, thermal or painful sensation (s) in the distal region of the legs; ii.&#xD;
             hypoactive or abolished achilles reflexes;&#xD;
&#xD;
          -  Glycated hemoglobin ≤ 11%;&#xD;
&#xD;
          -  Score ≥ 12 points on the LANSS pain scale (Leeds Assessment of Neuropathic Symptoms&#xD;
             and Signs); j) Participants with moderate to severe pain, a score ≥ 4 on the numerical&#xD;
             pain scale (0-10 points);&#xD;
&#xD;
          -  Participants with moderate to severe neuropathic pain who recorded in the diary a&#xD;
             minimum of 4 of the 7 days from the period to assess the baseline pain score.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to the formula components used during the clinical trial;&#xD;
&#xD;
          -  History of alcohol and/or substance abuse within 2 years;&#xD;
&#xD;
          -  Pregnant women, breastfeeding or planning to become pregnant, or women with the&#xD;
             potential to become pregnant who are not using a reliable method of contraception;&#xD;
&#xD;
          -  History of pernicious anemia, uncontrolled hypothyroidism, chronic hepatitis B;&#xD;
&#xD;
          -  HIV diagnosis;&#xD;
&#xD;
          -  History of neurological disorder unrelated to diabetic neuropathy;&#xD;
&#xD;
          -  Non-responders to previous pregabalin treatment;&#xD;
&#xD;
          -  High variability in the baseline pain score;&#xD;
&#xD;
          -  Other conditions that may alter the sensitivity in the affected dermatome or in the&#xD;
             area involved in neuropathic pain that may confuse pain assessment;&#xD;
&#xD;
          -  Severe psychiatric condition;&#xD;
&#xD;
          -  Cognitive decline that affect the participant from correctly answering the scales and&#xD;
             questionnaires;&#xD;
&#xD;
          -  Clinically relevant cardiac abnormalities, which at the researcher's discretion&#xD;
             represent a risk to participation in the trial;&#xD;
&#xD;
          -  Participant who has amputated lower limb due to complications from diabetes;&#xD;
&#xD;
          -  Renal failure, defined by the estimated glomerular filtration rate [eGFR] &lt;60 mL / min&#xD;
             / 1.73 m2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa FB Oliveira, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ncfarma.com.br</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

